DaVita IncNYSE: DVA
Health Care · Health Care Services
$205.47
+3.43%
Vol: 41K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21DaVita announced its 2030 Community Care Commitments on May 18 after exceeding prior five-year ESG goals, with the stock up 76% YTD on the back of Q1 EPS of $2.87 crushing $2.33 consensus.Positive▶
DaVita's May 5 Q1 results sent the stock up 23.5% in a single session, with EPS of $2.87 vs $2.33 consensus on revenue of $3.42B vs $3.36B expected, leading the company to raise full-year adjusted profit guidance. The company repurchased 2.0M shares for $302M (avg $149.81) between March 31 and May 5. CFO Joel Ackerman and IR VP Nic Eliason participated in the BofA Securities Health Care Conference on May 6. On May 18, DaVita unveiled its 2030 Community Care commitments focused on patient outcomes, teammate economic opportunity, and environmental resilience. Stock traded at $199.74 on May 15 (+3.7% on the day, +38.2% over the month). Multiple analyst PT hikes followed Q1: UBS to $235 from $190 (May 7), Truist to $205 from $158 (May 8), TD Cowen to $201 from $144 (May 10).
May 20DaVita CFO sells $2.9M in shares as stock trades near 2026 highs after Q1 blowoutPositive▶
DaVita's Chief Compliance Officer James Hearty sold approximately 15,000 shares worth $2.91M on May 15, 2026 at prices between $193.36 and $199.84. The stock remains near 2026 highs, up 76.5% YTD versus the S&P 500's 8.1% gain, following a strong Q1 print (EPS $2.87 vs $2.33 consensus, revenue $3.42B). On May 18, DaVita unveiled bold 2030 Community Care commitments after exceeding prior five-year ESG goals. Recent analyst actions include Deutsche Bank upgrading to Buy with a $220 target (from $126) and TD Cowen lifting its target to $201 (Hold). The company also raised full-year adjusted operating income and EPS guidance, citing additional volume from competitor clinic closures.
May 19TD Cowen raised DaVita PT to $201 from $144 (Hold) on May 11 after Q1 EPS of $2.87 crushed $2.33 consensus.Positive▶
DaVita reported Q1 2026 results on May 5 with EPS of $2.87, well above the $2.33 consensus, on revenue of $3.42B vs $3.36B expected, and raised its full-year adjusted profit forecast on higher treatment volume, productivity, and technology investments. Consolidated revenue was $3.416B with operating income of $482M, operating cash flow of $321M, and free cash flow of $140M. The stock surged 23.5% on the print and is now up 76.5% YTD vs SPX +8.1%. The company repurchased 3.0M shares for $403M in Q1 (avg $133.70) and 2.0M more shares between April 1 and May 5 for $302M (avg $149.81). On May 11, TD Cowen raised PT to $201 from $144 (Hold) and UBS raised PT to $190 from $186 (Buy). On May 12, COO David Maughan sold 20,529 shares. Shares traded near $199.81 on May 18.
May 18DaVita stock rose 3.7% on May 15 to $199.74 amid a 76% YTD rally, driven by Q1 2026 EPS of $2.87 (beating $2.33 consensus) and multiple analyst price target hikes including TD Cowen to $201.Positive▶
DaVita reported Q1 2026 results on May 5 with revenue of $3.42B (vs $3.36B est), operating income of $482M, and diluted EPS from continuing operations of $2.87 (smashing $2.33 consensus), triggering a 23.5% single-session jump. The company had 62,600 patients in risk-based integrated care representing $5.4B in annualized medical spend. Aggressive buybacks continued: 3.0M shares repurchased in Q1 for $403M ($133.70 avg), plus 2.0M additional shares for $302M ($149.81 avg) through May 5. TD Cowen raised PT to $201 from $144 (Hold) on May 11; Truist, UBS, and Barclays also raised targets. Stock has climbed 76.5% in 2026, trading at $199.74 on May 15. CFO Joel Ackerman participated in BofA Securities 2026 Health Care Conference on May 12. Eight-analyst consensus is Moderate Buy.
May 15DaVita extends 6-day rally to +31%; UBS lifts PT to $235, Truist to $205 after blowout Q1 EPS of $2.87 vs $2.33 consensusPositive▶
DaVita shares hit a 6-day winning streak with cumulative gains of 31%, and the stock is up 76.5% YTD vs SPX +8.1%. The rally followed Q1 2026 results on May 5 showing EPS of $2.87 versus $2.33 consensus (+43.5% YoY) and revenue of $3.42B versus $3.36B expected (+6% YoY). Operating income reached $482M; operating cash flow was $321M with $140M free cash flow. DaVita raised FY26 adjusted EPS guidance to $14.10-$15.20 and adjusted operating income to $2.15B-$2.25B. The company repurchased 3.0M shares for $403M in Q1 and another 2.0M for $302M between April 1-May 5 at avg $149.81. Integrated kidney care now covers 62,600 patients representing $5.4B annualized medical spend. UBS raised PT to $235 from $190; Truist to $205 from $158. Risk: rapid run-up may have priced in much of the upside.
May 14DaVita stock up 76.5% YTD after Q1 EPS beat, with UBS and Truist hiking PTs sharplyPositive▶
DaVita reported Q1 2026 results on May 5 with consolidated revenues of $3.416B, operating income of $482M, diluted EPS from continuing operations of $2.87, and free cash flow of $140M. Adjusted operating profit grew 10% YoY and adjusted EPS grew 44%, with the company raising its 2026 operating profit and adjusted EPS outlook. Shares popped 23.5% the day after earnings and are up 76.5% year-to-date and 38.9% over the past year. Recent analyst PT hikes include Truist raising to $205 from $158, UBS to $235 from $190, and Barclays to $194 from $158. Consensus rating is Moderate Buy with $190.50 mean PT and Street-high of $235. Elara Caring, a DaVita-affiliated company, secured strategic investment from Ares and DaVita in February to expand home health care.
May 13DaVita surged on a 6-day streak gaining 31% after Q1 EPS of $2.87 crushed $2.33 consensus and triggered widespread analyst upgradesPositive▶
DaVita reported Q1 2026 results on May 5, 2026, with EPS of $2.87 (vs $2.33 consensus, +43.5% YoY) on revenue of $3.42B (vs $3.36B expected, +6% YoY). The company raised FY26 adjusted EPS guidance to $14.10-$15.20 and raised adjusted operating income outlook to $2.15B-$2.25B. Between March 31 and May 5, DaVita repurchased 2.0M shares for $302M at $149.81 average. The stock posted a 6-day winning streak gaining 31%. Higher reimbursement rates and aggressive buybacks drove EPS gains despite soft dialysis volume. Deutsche Bank upgraded to Buy from Hold, and multiple firms raised price targets: Truist to $205, UBS to $235, Barclays to $194. CFO presented at BofA on May 12.
May 12DaVita CFO and IR head fireside chat at BofA Healthcare Conference today (May 12), capping a 5-day, 31% rally on Q1 beat and raised 2026 guidance.Positive▶
DaVita executives appear at the BofA Securities 2026 Health Care Conference at 5:20 pm ET on May 12. The event follows a May 5 Q1 blowout (EPS $2.87 vs $2.35 consensus, revenue $3.42B vs $3.36B) and a raised 2026 adjusted EPS outlook to $14.10-$15.20 with adjusted operating income of $2.15-$2.25B. Shares hit an all-time high near $198.65 on May 11 after a 23.5% gap on the print and a cumulative 31% 5-day gain. Multiple analysts hiked targets (Truist to $205, UBS to $235, Barclays to $194; Deutsche Bank upgraded to Buy). Bear case: insider sale by James Hearty and the magnitude of the rally raise the bar for the BofA fireside.
May 11DaVita stock surged 19.6% after blowout Q1 2026 EPS beat ($2.87 vs $2.33) and guidance raise.Positive▶
DaVita posted Q1 2026 EPS of $2.87, smashing the $2.33 consensus by $0.54, on revenue of $3.42B vs $3.36B expected (+6% YoY). Year-over-year EPS jumped 43.5% with margin expansion and dialysis volume strength. Management raised 2026 adjusted EPS guidance to $14.10-$15.20 (midpoint above consensus). DVA ripped to a $190.26 intraday high on May 6, closing at $188.70 (+19.6%). The company repurchased 2.0M shares for $302M at $149.81 average through May 5. Zacks Research upgraded to Strong-Buy; Deutsche Bank upgraded to Buy with PT raised to $220; Truist raised PT to $205. BofA Health Care Conference appearance set for May 12.
May 8Q1 EPS $2.87 crushes $2.33 est (+23%); 2026 guidance raised; stock surges 23.5% on May 6Positive▶
DaVita reported exceptional Q1 2026 with adjusted EPS of $2.87 beating $2.33 consensus by 23.2% on revenue of $3.42B. Company raised full-year 2026 adjusted EPS guidance to $14.10-$15.20 range. Year-over-year EPS jumped 43.5% driven by higher reimbursement rates and share buybacks despite soft dialysis volumes. Stock ripped from $157.04 to $193.88 close (+23.5%) on May 6, peaking intraday at $194.29. UBS raised PT from $190 to $235; Deutsche Bank raised to $220.
May 7DaVita beats Q1 EPS expectations with $2.87 earnings, Berkshire Hathaway sells $182.8M stakePositive▶
DaVita reported Q1 2026 diluted EPS of $2.87, beating consensus estimate of $2.33, with consolidated revenues of $3.416 billion and operating income of $482 million. Berkshire Hathaway sold 1,220,376 shares totaling approximately $182.8 million on May 1, 2026. The company will participate in the BofA Securities 2026 Health Care Conference on May 12. Stock declined 0.45% despite strong results as healthcare sector remained flat. Full-year adjusted EPS guidance of $14.10-$15.20 versus consensus of $14.12.
May 6DaVita Beats Q1 2026 Estimates, Raises Full-Year EPS GuidancePositive▶
DaVita reported Q1 2026 results on May 5 beating estimates with revenue of $3.42B, up 6% YoY, and non-GAAP EPS of $2.87, 23.2% above analyst consensus of $2.34. Strong U.S. dialysis performance drove results with shares rising 1.88% after-hours. Management raised full-year guidance expecting adjusted operating income between $2.15-2.25B and EPS between $14.10-15.20. Elara Caring secured new strategic investment from Ares and DaVita in February 2026. However, Berkshire Hathaway sold 1.22M shares on May 1 for $182.8M.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.